



## Lisata Therapeutics to Webcast Live at the Life Sciences Investor Forum on March 9th

March 6, 2023

***Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com***

**BASKING RIDGE, NJ (March 6, 2023)** – Lisata Therapeutics, Inc. (Nasdaq: LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that management will present live at the Life Science Investor Forum, hosted by VirtualInvestorConferences.com, on March 9, 2023.

**DATE:** March 9th, 2023

**TIME:** 10:30 a.m. – 11:00 a.m. Eastern Time

**LINK:** <https://bit.ly/3loXpvP>

### About Lisata Therapeutics

Lisata Therapeutics is a [clinical-stage pharmaceutical company](#) dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of [advanced solid tumors](#) and other major diseases. Lisata's lead investigational product candidate, [LSTA1](#) (formerly known as CEND-1), is designed to modify the tumor microenvironment by activating a novel uptake pathway that allows anti-cancer drugs to penetrate solid tumors more effectively. LSTA1 actuates an active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are not affected. LSTA1 has demonstrated favorable safety, tolerability, and activity in clinical trials to enhance delivery of standard-of-care chemotherapy for pancreatic cancer. Lisata and its collaborators have also amassed significant non-clinical data demonstrating enhanced delivery of a range of emerging anti-cancer therapies, including immunotherapies and RNA-based therapeutics. Lisata is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors more effectively. In addition, Lisata also has clinical development programs based on its autologous CD34+ cell therapy technology platform. For more information on the Company, please visit [www.lisata.com](http://www.lisata.com).

### Contact:

Investors and Media:

Lisata Therapeutics, Inc.

John Menditto

Vice President, Investor Relations and Corporate Communications

Phone: 908-842-0084

Email: [jmenditto@lisata.com](mailto:jmenditto@lisata.com)